Dronabinol for the reduction of chronic pain and inflammation in people with sickle cell disease

屈大麻酚可减轻镰状细胞病患者的慢性疼痛和炎症

• 批准号: 10676238
• 负责人: Susanna Curtis
• 金额: $ 19.33万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10676238
• 关键词: Address; Adult; Adverse effects; Adverse event; Advisory Committees; Anti-Inflammatory Agents; Anxiety; Benefits and Risks; Cannabinoids; Cannabis; Chemicals; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Design; Controlled Study; Cross-Sectional Studies; Data; Data Analyses; Desire for food; Development; Development Plans; Disease; Dizziness; Dronabinol; Emotional; Etiology; Event; FDA approved; Feasibility Studies; Fellowship; Funding; Future; Guidelines; IL4 gene; IL6 gene; Incidence; Individual; Inflammation; Inhalation; Institution; Interleukin-10; K-Series Research Career Programs; Knowledge; Legal; Marijuana; Masks; Measures; Mentored Patient-Oriented Research Career Development Award; Mentorship; Modeling; Moods; Nausea; Neuropathy; Nociception; Opioid; Oral; Organ; Outcome; Pain; Pain Measurement; Pain management; Participant; Patient Self-Report; Patients; Persons; Pharmacologic Substance; Placebo Control; Placebos; Positioning Attribute; Procedures; Provider; Quality of life; Randomized; Reporting; Research; Research Personnel; Research Project Grants; Risk; Route; Safety; Severities; Sickle Cell Anemia; Sleep; Social Impacts; Socioeconomic Factors; Statistical Data Interpretation; Sterility; Substance P; TNF gene; Techniques; Terpenes; Tetrahydrocannabinol; Tissues; Translational Research; Tryptase; cannabinoid treatment; capsule; career; career development; chronic pain; chronic pain management; clinical trial analysis; cognitive function; cytokine; double-masked controlled study; efficacious treatment; efficacy study; experience; health care service utilization; implementation research; improved; inflammatory marker; inflammatory pain; marijuana use; marijuana user; monocyte; mouse model; multidisciplinary; nerve damage; neuroinflammation; neutrophil; opioid use; pain relief; painful neuropathy; placebo group; prevent; primary outcome; psychologic; randomized trial; research and development; statistics

Dr. Curtis seeks to become an independently funded investigator in sickle cell disease with a focus on the understanding and treatment of chronic pain. Chronic pain is a critical issue for people with sickle cell disease (SCD). This pain is primarily treated with opioids, but for many people with SCD opioids are inadequate to treat chronic pain alone. Cannabinoids (the primary active agents in marijuana) have been shown to be effective for chronic and neuropathic pain and reduce inflammation in non-SCD diseases. Inflammation in SCD is not only correlated with pain but is also correlated with high rates of end organ damage. Over one third of people with SCD say they use cannabis for pain relief, but there is currently no evidence to support this use. Further, there is no evidence to suggest what the adverse effects of this use might be for people with SCD. There are no guidelines for what doctors should tell patients with SCD who ask if cannabis products might help their pain. This proposal seeks to address this gap with a placebo-controlled, double-masked, 8 week-long study of dronabinol, an FDA approval oral agent which contains tetrahydrocannabinol (THC), the primary active ingredient in cannabis. The aims of this study are 1: To determine whether dronabinol will improve pain and QOL in adults with SCD and chronic pain, 2: To assess dronabinol's effect on markers of inflammation in patients with SCD compared to placebo, And 3: To determine the safety and tolerability of dronabinol use in adults with SCD compared to placebo. If dronabinol is found to improve chronic pain, or quality of life, or to reduce markers of inflammation, it should studied in a larger trial. Understanding the safety and tolerability of dronabinol will guide not only future studies but will help clinicians and patients understand some of the possible risks of cannabis use. Through this career development award Dr. Curtis will gain expertise in clinical trial design and execution, longitudinal data analysis and advanced modelling techniques, and clinical and translational aspects of the study of chronic pain. Her advisory committee consists of experts in clinical trial development, pain in SCD, inflammation in SCD, and statistics. Through working with a multidisciplinary mentorship team, the proposed research project, and formal coursework, Dr. Curtis will be able to become an independent clinical investigator with expertise in chronic pain treatment in sickle cell disease.

他寻求成为镰状细胞病的独立资助研究者

项目成果

Long live the red blood cell: biotin tagging in SCD.

红细胞万岁：SCD 中的生物素标记。

• DOI: 10.1182/bloodadvances.2023012245
• 发表时间: 2024
• 期刊: Blood advances
• 影响因子: 7.5
• 作者: McCuskee,Sarah;Curtis,Susanna
• 通讯作者: Curtis,Susanna

COVID19 vaccination in adults with sickle cell disease is not associated with increases in rates of pain crisis.

• DOI: 10.1080/16078454.2022.2085072
• 发表时间: 2022-12
• 期刊: HEMATOLOGY
• 影响因子: 1.9
• 作者: Friedman, Elana;Minniti, Caterina;Campbell, Sean;Curtis, Susanna
• 通讯作者: Curtis, Susanna

Excess deaths among adults with sickle cell disease in 2020 compared to prior years.

• DOI: 10.1007/s00277-022-04994-6
• 发表时间: 2023-01
• 期刊: Annals of hematology
• 影响因子: 3.5
• 作者: Curtis S;Henny B;Joanna S;Betancourt J;Thomas M;Vattappally L;Crouch A;Caterina M
• 通讯作者: Caterina M

Is CBD ready for prime time in sickle cell disease?

CBD 准备好迎接镰状细胞病的黄金时期了吗？

• DOI: 10.1182/blood.2022018393
• 发表时间: 2023
• 期刊: Blood
• 影响因子: 20.3
• 作者: Curtis,SusannaA;Novelli,EnricoM
• 通讯作者: Novelli,EnricoM